Patient characteristics and overall responses to treatment at CML diagnosis with e1a2 BCR-ABL fusion transcripts
| Characteristic . | CP, n = 9 . | AP (CP + CE), n = 1 . | BP, n = 4 . |
|---|---|---|---|
| No. of patients | 9 | 1 | 1:MyBP, 3:LyBP |
| Median age at CML diagnosis, y (range) | 60 (28-86) | 46 | 60.5 (47-66) |
| Median follow-up after CML diagnosis, mo (range) | 57 (3-109) | 55 | 12.5 (8-40) |
| Median time from CML dx to treatment, mo (range) | 0.5 (0-2) | 1 | 0.25 (0-0.5) |
| IFN therapy before TKI, no. (%) | 3 (33) | — | — |
| TKI as first line (alone or in combination), no. (%) | 6 (67) | 1 (100) | 3 (75), all LBP |
| Evolution into AP | 1 (11) | — | — |
| Evolution into BP | 4 (44) | 0 | n/a |
| Median overall survival, mo (range) | 56 (3+ to 109) | 55+ | 13 (8-40) |
| Number surviving | 5 (56) | 1 (100) | 0 |
| BCR-ABL/KD mutations at relapse | 2* of 7 (29) | NA | 2 of 2* (100) |
| Characteristic . | CP, n = 9 . | AP (CP + CE), n = 1 . | BP, n = 4 . |
|---|---|---|---|
| No. of patients | 9 | 1 | 1:MyBP, 3:LyBP |
| Median age at CML diagnosis, y (range) | 60 (28-86) | 46 | 60.5 (47-66) |
| Median follow-up after CML diagnosis, mo (range) | 57 (3-109) | 55 | 12.5 (8-40) |
| Median time from CML dx to treatment, mo (range) | 0.5 (0-2) | 1 | 0.25 (0-0.5) |
| IFN therapy before TKI, no. (%) | 3 (33) | — | — |
| TKI as first line (alone or in combination), no. (%) | 6 (67) | 1 (100) | 3 (75), all LBP |
| Evolution into AP | 1 (11) | — | — |
| Evolution into BP | 4 (44) | 0 | n/a |
| Median overall survival, mo (range) | 56 (3+ to 109) | 55+ | 13 (8-40) |
| Number surviving | 5 (56) | 1 (100) | 0 |
| BCR-ABL/KD mutations at relapse | 2* of 7 (29) | NA | 2 of 2* (100) |
CP indicates chronic phase; AP, accelerated phase; CE, clonal evolution; BP, blast phase; MyBP, myeloid blast phase; LyBP, lymphoid blast phase; PB, peripheral blood; BM, bone marrow; IFN, interferon; TKI, tyrosine kinase inhibitor; KD, kinase domain; dx, diagnosis; mo, months; and —, none.
Mutations: E459K in CP patients; V299L and T315I in BP patients.